Wahl R L
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028.
Cancer. 1994 Feb 1;73(3 Suppl):989-92. doi: 10.1002/1097-0142(19940201)73:3+<989::aid-cncr2820731336>3.0.co;2-u.
This overview highlights the use of experimental models in selecting monoclonal antibodies and radiolabels with promise for clinical radioimmunotherapy, discusses some of the experimental therapeutic approaches being studies in these models, and reviews some of the limitations of animal models caused by the allometric and other differences between man and mouse. These differences in scale must be considered when attempting to extrapolate animal radioimmunotherapy study data to human trials of radioimmunotherapy. With appropriate recognition of their limitations, experimental models of radioimmunotherapy have proven valuable and will continue to play a critical role as the place to first study innovations in radioimmunotherapy, before extension of the most promising reagents and treatment concepts into clinical therapeutic trials.
本综述重点介绍了实验模型在筛选有望用于临床放射免疫治疗的单克隆抗体和放射性标记物方面的应用,讨论了在这些模型中正在研究的一些实验性治疗方法,并回顾了由于人与小鼠之间的异速生长及其他差异而导致的动物模型的一些局限性。在试图将动物放射免疫治疗研究数据外推至人类放射免疫治疗试验时,必须考虑这些尺度上的差异。尽管认识到其局限性,但放射免疫治疗的实验模型已证明具有价值,并将继续发挥关键作用,作为首先研究放射免疫治疗创新的场所,之后再将最有前景的试剂和治疗理念扩展到临床治疗试验中。